Microbiotix, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of proprietary small molecule drugs that target serious infectious diseases, including multi-drug resistant pathogens.
The Company’s lead therapeutic compound, MBX-400, is a potent and novel nucleoside analog dual DNA polymerase/kinase inhibitor for the treatment of human cytomegalovirus (CMV). MBX-400 has successfully completed Phase 1 clinical testing.
The Company is also advancing several innovative antibacterial programs focusing on multidrug-resistant pathogens.
CARB-X funds Microbiotix to develop a novel oral antibiotic to treat multidrug-resistant gonorrhea – March 17, 2020 (PDF)
Microbiotix presents new data at the ASM Microbe 2018 Conference – June 7, 2018 (PDF)
Microbiotix and the AMR Centre Announce Co-Development Agreement Targeting Drug Resistant P. aeruginosa in Critically Ill Pneumonia Patients – September 14, 2017 (PDF)
CARB-X injects up to $48 million to accelerate first Powered by CARB-X portfolio of drug discovery and development projects to tackle antibiotic resistance – March 30, 2017 (PDF)